CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Expenses:
Research and development	$ 3,241	$ 3,179
General and administrative	3,360	3,665
Total operating expenses	6,601	6,844
Operating loss	(6,601)	(6,844)
Other income (expense):
Investment income, net	589	670
Other expense, net	(187)	(13)
Total other income	402	657
Net loss before benefit from income taxes and noncontrolling interests	(6,199)	(6,187)
Benefit from income taxes	(798)	0
Net loss	(5,401)	(6,187)
Less - net income (loss) attributable to noncontrolling interests	0	0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders	$ (5,401)	$ (6,187)
Basic and diluted loss per share
Lisata Therapeutics, Inc. common stockholders- basic (in usd per share)	$ (0.65)	$ (0.77)
Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share)	$ (0.65)	$ (0.77)
Weighted average common shares outstanding
Basic shares (in shares)	8,294	7,987
Diluted shares (in shares)	8,294	7,987